Morepen Labs Approves Q1 FY27 Results, Dividend Record Date, and CMD Re-appointment
Morepen Laboratories approved Q1 FY27 results. A dividend record date of September 19, 2026, was set. The Medical Devices Business divestment timeline was extended. Mr. Sushil Suri was re-appointed as CMD for three years from October 20, 2026. The 41st AGM is on September 26, 2026.
The re-appointment of the CMD and the approval of financial results and dividend are significant for the company's governance and shareholder returns. The extension of the business divestment timeline provides clarity on strategic direction.
The company reported financial results, declared a dividend record date, approved the extension of a business divestment timeline, and re-appointed its Chairman & Managing Director, all of which are positive corporate actions.
Morepen Laboratories Limited's Board of Directors, in a meeting held on August 4, 2026, approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also set Saturday, September 19, 2026, as the record date for determining eligibility for the final dividend for the financial year ended March 31, 2026, subject to member approval at the 41st Annual General Meeting (AGM).
Further, the board approved the extension of the timeline for hiving off the Medical Devices Business into its subsidiary, Morepen Medipath Limited, as a going concern on a slump sale basis, pending member approval at the 41st AGM.
In a significant decision, the board approved the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, effective from October 20, 2026, to October 19, 2029, subject to member approval at the 41st AGM. Mr. Suri, a qualified Chartered Accountant with over 30 years of experience in the pharmaceutical industry, is the brother of Mr. Sanjay Suri, the company's Managing Director. The 41st AGM is scheduled to be held on Saturday, September 26, 2026, via video conferencing.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.